PRP in 2ry Spontaneous Pneumothorax

NCT ID: NCT03830645

Last Updated: 2020-06-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-05

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

secondary spontaneous pneumothorax patients will be enrolled ,all of them will receive PRP with different doses and schedules

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumothorax Spontaneous Secondary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Platelet rich plasma group

Group Type EXPERIMENTAL

Platelet Rich Plasma

Intervention Type BIOLOGICAL

Application of platelet rich plasma through the intercostal tube into the pleural space

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Platelet Rich Plasma

Application of platelet rich plasma through the intercostal tube into the pleural space

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COPD patients developed spontanous pneumothorax and was managed with intercostal tube insertion

Exclusion Criteria

* refusal of participation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zagazig University

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmad Abbas

Principal investigator &lecturer of chest disases zagazig university

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zagazig University Faculty of medicine Chest Department

Zagazig, Asharqia, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ahmad Abbas, MD

Role: CONTACT

201155355369

Mohammed Walaa, MD

Role: CONTACT

201002089696

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ahmad Abbas, MD

Role: primary

201155355369

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZU-IRB#4931-4-11-2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Stop Air Leak by Talc or Autologous Blood Patch Therapy
NCT06883188 NOT_YET_RECRUITING PHASE2/PHASE3